A Phase 3 interventional study of mycophenolate mofetil and mycophenolate mofetil in Kidney Transplantation, sponsored by Hoffmann-La Roche. Completed at 24 sites in France. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2015-11-11.
Sponsored by Hoffmann-La Roche · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
This study will compare the incidence of acute clinical or subclinical rejection between immunosuppression with CellCept at a starting dose of 3mg po daily with therapeutic drug monitoring and standard immunosuppression with CellCept and a fixed dose of 2g po daily, in kidney transplant recipients receiving induction by anti-IRL2, cyclosporine therapy, and early discontinuation of steroids. Patients will be randomized to one of the two treatment arms. The anticipated time on study treatment is 52 weeks.
Hoffmann-La Roche is the lead sponsor of 2,102 studies on the registry; 89 are open to participants now.
Of its 330 completed or terminated interventional studies of FDA-regulated products, 248 (75%) have results posted.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants received 3 grams (g) mycophenolate mofetil (MMF) tablets per os (p.o.) in divided doses (every 12 hours \[q12h\]) adapted to mycophenolic acid (MPA) by area under the curve (AUC) beginning on the day of renal transplant, Day 0, or the day before, Day -1, and continuing through Week 52. In addition, induction by interleukin-2R (IL-2R) was administered at Day 0 per standard of care at the site at the investigator's discretion. At 72 hours post-transplantation, participants received cyclosporine 100-1500 nanograms (ng) per (/) milliliter (mL) from Day 0 to (-) Week 4, 800-1200 ng/mL from Week 4 - Week 12 and 500-800 ng/mL from Week 12 - Week 52. Solumedrol 500 mg intravenously (i.v.) was administered before or after the transplantation, and 0.5 milligrams (mg) per kilogram (kg) p.o. daily from Day 1 - Day 7.
Drug: mycophenolate mofetil · Drug: anti-IL-2R · Drug: methylprednisolone · Drug: cyclosporine
Participants received 2 g MMF tablets p.o. in divided doses q12h beginning on the day of renal transplant, Day 0, or the day before, Day -1, and continuing through Week 52. In addition, induction by IL-2R was administered at Day 0 per standard of care at the site at the investigators discretion. At 72 hours post-transplantation, participants received cyclosporine 100-1500 ng/mL from Day 0 - Week 4, 800-1200 ng/mL from Week 4 - Week 12 and 500-800 ng/mL from Week 12 - Week 52. Solumedrol 500 mg i.v. was administered before or after the transplantation, and 0.5 mg/kg p.o. daily from Day 1 - Day 7.
Drug: mycophenolate mofetil · Drug: anti-IL-2R · Drug: methylprednisolone · Drug: cyclosporine
3 g p.o. in divided doses q12h beginning on the day of renal transplant, Day 0, or the day before, Day -1, and continuing to Week 52, adapted to MPA by AUC on Weeks 2, 6, 12, 26, and 52 to obtain AUC0-12 of 50 milligrams (mg) multiplied by (\*) height (h)/ liter(L).
Also known as: CellCept
2 g p.o. in divided doses q12h beginning on the day of renal transplant, Day 0, or the day before, Day -1, and continuing to Week 52.
Also known as: CellCept
Induction by IL-2R was administered at Day 0 per standard of care at the site at the investigators discretion.
500 mg intravenous (i.v.) was administered before or after the transplantation, and 0.5 mg/kg p.o. daily from Day 1 to Day 7.
Also known as: Solumedrol
100-1500 nanograms (ng) per milliliter (mL) from Day 0 to Week 4, 800-1200 ng/mL from Week 4 to Week 12 and 500-800 ng/mL from Week 12 to Week 52
Percentage of Participants With Biopsy-Proven Acute Rejection (BPAR) Before Week 12 or Acute Subclinical Rejection on Protocol Biopsy at Week 12
BPAR was defined as the presence of clinical signs and kidney biopsy that confirmed the rejection before Week 12. Subclinical acute rejection was defined as an increase of serum creatinine at Week 12 strictly less than 10 percent (%) compared to baseline (BL) values and BPAR of Grade greater than or equal to (≥) 1 according to Banff 1997 classification at Week 12.
Time frame: Week 12
Serum Creatinine Values [Micromoles Per Liter (µmol/L)]
The mean serum creatinine values at Weeks 2, 4, 6, 12, 16, 26, 39, and 52.
Time frame: Weeks 2, 4, 6, 12, 16, 26, 39, and 52
Creatinine Clearance Values Estimated With the Cockcroft-Gault Equation (Milliliters Per Minute [mL/Min])
The mean creatinine clearance values at Weeks 2, 4, 6, 12, 16, 26, 39, and 52 estimated using the Cockcroft-Gault equation.
Time frame: Weeks 2, 4, 6, 12, 16, 26, 39, and 52
Creatinine Clearance Values Estimated With the Modification of Diet in Renal Disease (MDRD) Simplified Equation
The mean creatinine clearance values at Weeks 2, 4, 6, 12, 16, 26, 39, and 52 estimated using the MDRD simplified equation. For males, the MDRD simplified equation was defined as MDRD (mL/min/1.73 square meters \[m\^2\]) =186 multiplied by (\*) serum creatinine in mg/L raised to the power of (\^) -1.154 \* age \^ -0.203. For females, the MDRD simplified equation was defined as MDRD (mL/min/1.73 m\^2) = males formula \* 0.742.
Time frame: Weeks 2, 4, 6, 12, 16, 26, 39, and 52
Time to Occurrence of First BPAR Between Day 0 and Week 52 - Percentage of Participants With an Event
BPAR was defined as the presence of clinical signs and kidney biopsy that confirmed the rejection before Week 12. Subclinical acute rejection at Week 12 was included in the analysis. Subclinical acute rejection was defined as an increase of serum creatinine at Week 12 strictly less than 10% compared to BL values and BPAR of Grade ≥1 according to Banff 1997 classification at Week 12. The occurrence of the first BPAR was defined as the time from randomization to the first recorded BPAR between Day 0 and Week 52. The results of protocol biopsies at Week 12 were taken into account. Participants were censored at the date of last treatment, date of last contact or withdrawal, and date of death.
Time frame: Day 0, Weeks 2, 4, 6, 12, 16, 26, 39, and 52
Time to Occurrence of First BPAR Between Day 0 and Week 52
BPAR was defined as the presence of clinical signs and kidney biopsy that confirmed the rejection before Week 12. Subclinical acute rejection at Week 12 was included in the analysis. Subclinical acute rejection was defined as an increase of serum creatinine at Week 12 strictly less than 10% compared to BL values and BPAR of Grade ≥1 according to Banff 1997 classification at Week 12. The occurrence of the first BPAR was defined as the time from randomization to the first recorded BPAR between Day 0 and Week 52. The results of protocol biopsies at Week 12 were taken into account. Participants were censored at the date of last treatment, date of last contact or withdrawal, and date of death.
Time frame: Day 0, Weeks 2, 4, 6, 12, 16, 26, 39, and 52
Percentage of Participants With at Least One BPAR at Week 12 and Week 52
BPAR was defined as the presence of clinical signs and kidney biopsy that confirmed the rejection before Week 12. Participants were censored at the date of last treatment, date of last contact or withdrawal, and date of death.
Time frame: Weeks 12 and 52
Graft Histology - Percentage of Participants With at Least One Borderline Lesion at Week 12 and Week 52
Participants were censored at the date of last treatment, date of last contact or withdrawal, and date of death.
Time frame: Weeks 12 and 52
Graft Histology - Percentage of Participants With at Least One Chronic Graft Nephropathy at Week 12 and Week 52
Participants were censored at the date of last treatment, date of last contact or withdrawal, and date of death.
Time frame: Weeks 12 and 52
Graft Loss - Percentage of Participants With an Event
Graft loss was defined as physical loss (nephrectomy), functional loss \[necessitating maintenance dialysis for greater than (\>)8 weeks\], retransplant or death. Participants were censored at the date of last treatment, date of last contact or withdrawal, and date of death.
Time frame: Day 0, Weeks 2, 4, 6, 12, 16, 26, 39, and 52
Time to Graft Loss
The median time, in days, from randomization to graft loss event. Participants were censored at the date of last treatment, date of last contact or withdrawal, and date of death.
Time frame: Day 0, Weeks 2, 4, 6, 12, 16, 26, 39, and 52
Participant Survival
Participants survival was defined as the percentage of participants living with or without a functioning graft between Weeks 0 and 52. Participants were censored at the date of last treatment, date of last contact or withdrawal, and date of death.
Time frame: Day 0, Weeks 2, 4, 6, 12, 16, 26, 39, and 52
| Milestone | Mycophenolate Mofetil, Adapted Dose | Mycophenolate Mofetil, Fixed Dose |
|---|---|---|
| Started | 127 | 125 |
| Transplanted | 126 | 121 |
| Completed | 115 | 110 |
| Not completed | 12 | 15 |
| Withdrew: Death | 2 | 2 |
| Withdrew: Graft loss | 7 | 6 |
| Withdrew: Withdrawal by subject | 2 | 2 |
| Withdrew: No transplant | 1 | 4 |
| Withdrew: Physician decision | 0 | 1 |
BPAR was defined as the presence of clinical signs and kidney biopsy that confirmed the rejection before Week 12. Subclinical acute rejection was defined as an increase of serum creatinine at Week 12 strictly less than 10 percent (%) compared to baseline (BL) values and BPAR of Grade greater than or equal to (≥) 1 according to Banff 1997 classification at Week 12.
| percentage of participants | Mycophenolate Mofetil, Adapted Dose | Mycophenolate Mofetil, Fixed Dose |
|---|---|---|
| Percentage of Participants With Biopsy-Proven Acute Rejection (BPAR) Before Week 12 or Acute Subclinical Rejection on Protocol Biopsy at Week 12 | 24.2 | 19.8 |
The mean serum creatinine values at Weeks 2, 4, 6, 12, 16, 26, 39, and 52.
| µmol/L | Mycophenolate Mofetil, Adapted Dose | Mycophenolate Mofetil, Fixed Dose |
|---|---|---|
| Week 2 (n=120,114) | 202.41 ± 144.80 | 201.31 ± 130.79 |
| Week 4 (n=119,113) | 168.92 ± 95.66 | 174.86 ± 77.67 |
| Week 6 (n=119,113) | 155.74 ± 84.01 | 158.96 ± 59.36 |
| Week 12 (n=117,112) | 140.80 ± 53.18 | 147.70 ± 50.38 |
| Week 16 (n=116,112) | 145.48 ± 83.00 | 148.48 ± 71.83 |
| Week 26 (n=115,112) | 131.73 ± 42.20 | 143.73 ± 46.87 |
| Week 40 (n=114,108) | 136.24 ± 45.84 | 141.89 ± 47.19 |
| Week 52 (n=115,110) | 148.62 ± 124.30 | 144.72 ± 47.37 |
The mean creatinine clearance values at Weeks 2, 4, 6, 12, 16, 26, 39, and 52 estimated using the Cockcroft-Gault equation.
| mL/min | Mycophenolate Mofetil, Adapted Dose | Mycophenolate Mofetil, Fixed Dose |
|---|---|---|
| Week 2 (n=120,114) | 46.68 ± 21.05 | 45.26 ± 18.93 |
| Week 4 (n=119,113) | 51.03 ± 19.17 | 46.73 ± 18.11 |
| Week 6 (n=119,113) | 53.66 ± 20.94 | 49.77 ± 19.05 |
| Week 12 (n=117,112) | 56.55 ± 19.40 | 53.01 ± 20.14 |
| Week 16 (n=116,112) | 56.55 ± 20.14 | 53.49 ± 19.72 |
| Week 26 (n=115,112) | 60.21 ± 21.35 | 55.18 ± 20.52 |
| Week 40 (n=114,108) | 59.17 ± 19.86 | 56.81 ± 21.81 |
| Week 52 (n=115,110) | 58.29 ± 20.42 | 56.45 ± 22.02 |
The mean creatinine clearance values at Weeks 2, 4, 6, 12, 16, 26, 39, and 52 estimated using the MDRD simplified equation. For males, the MDRD simplified equation was defined as MDRD (mL/min/1.73 square meters \[m\^2\]) =186 multiplied by (\*) serum creatinine in mg/L raised to the power of (\^) -1.154 \* age \^ -0.203. For females, the MDRD simplified equation was defined as MDRD (mL/min/1.73 m\^2) = males formula \* 0.742.
| mL/min/1.73 m^2 | Mycophenolate Mofetil, Adapted Dose | Mycophenolate Mofetil, Fixed Dose |
|---|---|---|
| Week 2 (n=120,114) | 40.61 ± 19.00 | 39.60 ± 18.74 |
| Week 4 (n=119,113) | 45.02 ± 16.58 | 41.31 ± 16.70 |
| Week 6 (n=119,113) | 48.12 ± 19.32 | 44.69 ± 16.69 |
| Week 12 (n=117,112) | 50.93 ± 16.27 | 47.68 ± 16.24 |
| Week 16 (n=116,112) | 50.93 ± 17.05 | 48.52 ± 17.42 |
| Week 26 (n=115,112) | 54.22 ± 16.76 | 49.46 ± 18.64 |
| Week 40 (n=114,108) | 52.23 ± 15.94 | 50.01 ± 18.69 |
| Week 52 (n=115,110) | 50.82 ± 16.33 | 48.88 ± 18.24 |
BPAR was defined as the presence of clinical signs and kidney biopsy that confirmed the rejection before Week 12. Subclinical acute rejection at Week 12 was included in the analysis. Subclinical acute rejection was defined as an increase of serum creatinine at Week 12 strictly less than 10% compared to BL values and BPAR of Grade ≥1 according to Banff 1997 classification at Week 12. The occurrence of the first BPAR was defined as the time from randomization to the first recorded BPAR between Day 0 and Week 52. The results of protocol biopsies at Week 12 were taken into account. Participants were censored at the date of last treatment, date of last contact or withdrawal, and date of death.
| percentage of participants | Mycophenolate Mofetil, Adapted Dose | Mycophenolate Mofetil, Fixed Dose |
|---|---|---|
| Time to Occurrence of First BPAR Between Day 0 and Week 52 - Percentage of Participants With an Event | 24.6 | 14.9 |
BPAR was defined as the presence of clinical signs and kidney biopsy that confirmed the rejection before Week 12. Subclinical acute rejection at Week 12 was included in the analysis. Subclinical acute rejection was defined as an increase of serum creatinine at Week 12 strictly less than 10% compared to BL values and BPAR of Grade ≥1 according to Banff 1997 classification at Week 12. The occurrence of the first BPAR was defined as the time from randomization to the first recorded BPAR between Day 0 and Week 52. The results of protocol biopsies at Week 12 were taken into account. Participants were censored at the date of last treatment, date of last contact or withdrawal, and date of death.
| days | Mycophenolate Mofetil, Adapted Dose | Mycophenolate Mofetil, Fixed Dose |
|---|---|---|
| Time to Occurrence of First BPAR Between Day 0 and Week 52 | NA (NA to NA) | NA (NA to NA) |
BPAR was defined as the presence of clinical signs and kidney biopsy that confirmed the rejection before Week 12. Participants were censored at the date of last treatment, date of last contact or withdrawal, and date of death.
| percentage of participants | Mycophenolate Mofetil, Adapted Dose | Mycophenolate Mofetil, Fixed Dose |
|---|---|---|
| Week 12 | 14.1 | 10.0 |
| Week 52 | 9.1 | 10.0 |
Participants were censored at the date of last treatment, date of last contact or withdrawal, and date of death.
| percentage of participants | Mycophenolate Mofetil, Adapted Dose | Mycophenolate Mofetil, Fixed Dose |
|---|---|---|
| Week 12 | 7.9 | 12.4 |
| Week 52 | 6.4 | 5.0 |
Participants were censored at the date of last treatment, date of last contact or withdrawal, and date of death.
| percentage of participants | Mycophenolate Mofetil, Adapted Dose | Mycophenolate Mofetil, Fixed Dose |
|---|---|---|
| Week 12 | 20.6 | 17.4 |
| Week 52 | 32.5 | 34.7 |
Graft loss was defined as physical loss (nephrectomy), functional loss \[necessitating maintenance dialysis for greater than (\>)8 weeks\], retransplant or death. Participants were censored at the date of last treatment, date of last contact or withdrawal, and date of death.
| percentage of participants | Mycophenolate Mofetil, Adapted Dose | Mycophenolate Mofetil, Fixed Dose |
|---|---|---|
| Graft Loss - Percentage of Participants With an Event | 5.6 | 5.0 |
The median time, in days, from randomization to graft loss event. Participants were censored at the date of last treatment, date of last contact or withdrawal, and date of death.
| days | Mycophenolate Mofetil, Adapted Dose | Mycophenolate Mofetil, Fixed Dose |
|---|---|---|
| Time to Graft Loss | NA ± NA | NA ± NA |
Participants survival was defined as the percentage of participants living with or without a functioning graft between Weeks 0 and 52. Participants were censored at the date of last treatment, date of last contact or withdrawal, and date of death.
| percentage of participants | Mycophenolate Mofetil, Adapted Dose | Mycophenolate Mofetil, Fixed Dose |
|---|---|---|
| Participant Survival | 98.4 | 98.3 |
Collected over All adverse events (AEs) were recorded from randomization (Day 0) through the end of study (Week 52).. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Mycophenolate Mofetil, Adapted Dose | — | 106/127 (83.5%) | 120/127 (94.5%) |
| Mycophenolate Mofetil, Fixed Dose | — | 94/125 (75.2%) | 115/125 (92%) |
| Event | Mycophenolate Mofetil, Adapted Dose | Mycophenolate Mofetil, Fixed Dose |
|---|---|---|
| Kidney transplant rejectionRenal and urinary disorders | 49/127 | 39/125 |
| Cytomegalovirus infectionInfections and infestations | 18/127 | 7/125 |
| Blood creatinine increasedInvestigations | 15/127 | 10/125 |
| Renal failure acuteRenal and urinary disorders | 14/127 | 11/125 |
| Renal impairmentRenal and urinary disorders | 9/127 | 9/125 |
| Pyelonephritis acuteInfections and infestations | 9/127 | 5/125 |
| PyelonephritisInfections and infestations | 8/127 | 7/125 |
| Graft dysfunctionInjury, poisoning and procedural complications | 6/127 | 6/125 |
| DiarrhoeaGastrointestinal disorders | 3/127 | 4/125 |
| NeutropeniaBlood and lymphatic system disorders | 3/127 | 3/125 |
| Event | Mycophenolate Mofetil, Adapted Dose | Mycophenolate Mofetil, Fixed Dose |
|---|---|---|
| AnaemiaBlood and lymphatic system disorders | 71/127 | 62/125 |
| LeukopeniaBlood and lymphatic system disorders | 42/127 | 23/125 |
| Urinary tract infectionInfections and infestations | 28/127 | 31/125 |
| Oedema peripheralGeneral disorders | 27/127 | 27/125 |
| HypertensionVascular disorders | 18/127 | 22/125 |
| Graft dysfunctionInjury, poisoning and procedural complications | 22/127 | 10/125 |
| DiarrheoaGastrointestinal disorders | 18/127 | 6/125 |
| DyslipidaemiaMetabolism and nutrition disorders | 13/127 | 17/125 |
| Diabetes mellitusMetabolism and nutrition disorders | 16/127 | 12/125 |
| Cytomegalovirus infectionInfections and infestations | 15/127 | 14/125 |
Intent-to-treat (ITT) population, all randomized renal transplant recipients who received at least 1 dose of MMF.
| Age, Continuous(years) | Mycophenolate Mofetil, Adapted Dose | Mycophenolate Mofetil, Fixed Dose | Total |
|---|---|---|---|
| Mean | 48.4 ± 13.2 | 48.5 ± 13.0 | 48.5 ± 13.1 |
| Sex: Female, Male(Participants) | Mycophenolate Mofetil, Adapted Dose | Mycophenolate Mofetil, Fixed Dose | Total |
|---|---|---|---|
| Female | 40 | 43 | 83 |
| Male | 86 | 78 | 164 |
The record gives a start of May 2006, a primary completion of Mar 2009 and a completion of Mar 2009. It does not say whether these dates are actual or estimated.
Results were first posted in Nov 2015, 6 years 8 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Oct 2015. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Mycophenolic Acid · Cyclosporine